PRRT – FDA Approves Lutathera®, What’s Next?
February 20, 2018
The FDA approval of Lutathera®, a peptide receptor radionuclide therapy (PRRT), on January 26, 2018 signals a new era in treatment options for the neuroendocrine cancer community. It has also raised a host of questions including:
- What exactly is this